The increase in price target by Baird, while maintaining a Neutral rating, suggests a positive adjustment in the valuation of CRISPR Therapeutics. This adjustment reflects an expectation of improved performance or valuation metrics, which could lead to increased investor interest and potentially a short-term uptick in the stock price.